Patents Assigned to SERODUS APS
  • IL-4 derived peptide fragments for use in the treatment of diabetic nephropathy
    Patent number: 12440535
    Abstract: The present disclosure relates to peptide fragments derived from interleukin-4 (IL-4) for the treatment of diabetic nephropathy.
    Type: Grant
    Filed: April 28, 2023
    Date of Patent: October 14, 2025
    Assignee: SERODUS APS
    Inventor: Eva Steiness
  • IL-4 derived peptides for use in the treatment of obesity
    Patent number: 12378294
    Abstract: The present disclosure relates to peptides derived from interleukin-4 (IL-4) for the treatment of obesity.
    Type: Grant
    Filed: January 4, 2023
    Date of Patent: August 5, 2025
    Assignee: SERODUS APS
    Inventor: Eva Steiness
  • IL-4 DERIVED PEPTIDE FRAGMENTS FOR USE IN THE TREATMENT OF DIABETIC NEPHROPATHY
    Publication number: 20250064887
    Abstract: The present disclosure relates to peptide fragments derived from interleukin-4 (IL-4) for the treatment of diabetic nephropathy.
    Type: Application
    Filed: April 28, 2023
    Publication date: February 27, 2025
    Applicant: SERODUS APS
    Inventor: Eva STEINESS
  • IL-4 DERIVED PEPTIDES FOR USE IN THE TREATMENT OF OBESITY
    Publication number: 20250059248
    Abstract: The present disclosure relates to peptides derived from interleukin-4 (IL-4) for the treatment of obesity.
    Type: Application
    Filed: January 4, 2023
    Publication date: February 20, 2025
    Applicant: SERODUS APS
    Inventor: Eva STEINESS
  • IL1RA DERIVED PEPTIDES FOR TREATMENT OF DIABETIC NEPHROPATHY
    Publication number: 20240216464
    Abstract: The present disclosure relates to peptides derived from IL-1R antagonist protein (IL1RA) for treatment of diabetic nephropathy and for use in treating diabetic nephropathy.
    Type: Application
    Filed: July 13, 2021
    Publication date: July 4, 2024
    Applicant: SERODUS APS
    Inventor: Eva STEINESS